226 related articles for article (PubMed ID: 23668926)
1. Dysregulation of mTOR activity through LKB1 inactivation.
Zhou W; Marcus AI; Vertino PM
Chin J Cancer; 2013 Aug; 32(8):427-33. PubMed ID: 23668926
[TBL] [Abstract][Full Text] [Related]
2. Loss of tuberous sclerosis complex-2 function and activation of mammalian target of rapamycin signaling in endometrial carcinoma.
Lu KH; Wu W; Dave B; Slomovitz BM; Burke TW; Munsell MF; Broaddus RR; Walker CL
Clin Cancer Res; 2008 May; 14(9):2543-50. PubMed ID: 18451215
[TBL] [Abstract][Full Text] [Related]
3. Stromal liver kinase B1 [STK11] signaling loss induces oviductal adenomas and endometrial cancer by activating mammalian Target of Rapamycin Complex 1.
Tanwar PS; Kaneko-Tarui T; Zhang L; Tanaka Y; Crum CP; Teixeira JM
PLoS Genet; 2012; 8(8):e1002906. PubMed ID: 22916036
[TBL] [Abstract][Full Text] [Related]
4. LKB1 and AMP-activated protein kinase control of mTOR signalling and growth.
Shaw RJ
Acta Physiol (Oxf); 2009 May; 196(1):65-80. PubMed ID: 19245654
[TBL] [Abstract][Full Text] [Related]
5. Hepatitis C virus inhibits AKT-tuberous sclerosis complex (TSC), the mechanistic target of rapamycin (MTOR) pathway, through endoplasmic reticulum stress to induce autophagy.
Huang H; Kang R; Wang J; Luo G; Yang W; Zhao Z
Autophagy; 2013 Feb; 9(2):175-95. PubMed ID: 23169238
[TBL] [Abstract][Full Text] [Related]
6. Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors.
Wagner AJ; Malinowska-Kolodziej I; Morgan JA; Qin W; Fletcher CD; Vena N; Ligon AH; Antonescu CR; Ramaiya NH; Demetri GD; Kwiatkowski DJ; Maki RG
J Clin Oncol; 2010 Feb; 28(5):835-40. PubMed ID: 20048174
[TBL] [Abstract][Full Text] [Related]
7. Altered LKB1/AMPK/TSC1/TSC2/mTOR signaling causes disruption of Sertoli cell polarity and spermatogenesis.
Tanwar PS; Kaneko-Tarui T; Zhang L; Teixeira JM
Hum Mol Genet; 2012 Oct; 21(20):4394-405. PubMed ID: 22791749
[TBL] [Abstract][Full Text] [Related]
8. Fibronectin stimulates non-small cell lung carcinoma cell growth through activation of Akt/mammalian target of rapamycin/S6 kinase and inactivation of LKB1/AMP-activated protein kinase signal pathways.
Han S; Khuri FR; Roman J
Cancer Res; 2006 Jan; 66(1):315-23. PubMed ID: 16397245
[TBL] [Abstract][Full Text] [Related]
9. Curcumin inhibits Akt/mammalian target of rapamycin signaling through protein phosphatase-dependent mechanism.
Yu S; Shen G; Khor TO; Kim JH; Kong AN
Mol Cancer Ther; 2008 Sep; 7(9):2609-20. PubMed ID: 18790744
[TBL] [Abstract][Full Text] [Related]
10. Cell-type-dependent regulation of mTORC1 by REDD1 and the tumor suppressors TSC1/TSC2 and LKB1 in response to hypoxia.
Wolff NC; Vega-Rubin-de-Celis S; Xie XJ; Castrillon DH; Kabbani W; Brugarolas J
Mol Cell Biol; 2011 May; 31(9):1870-84. PubMed ID: 21383064
[TBL] [Abstract][Full Text] [Related]
11. AMPK/TSC2/mTOR-signaling intermediates are not necessary for LKB1-mediated nuclear retention of PTEN tumor suppressor.
Liu JL; Mao Z; Gallick GE; Yung WK
Neuro Oncol; 2011 Feb; 13(2):184-94. PubMed ID: 21123367
[TBL] [Abstract][Full Text] [Related]
12. ER stress negatively regulates AKT/TSC/mTOR pathway to enhance autophagy.
Qin L; Wang Z; Tao L; Wang Y
Autophagy; 2010 Feb; 6(2):239-47. PubMed ID: 20104019
[TBL] [Abstract][Full Text] [Related]
13. Dual targeting of androgen receptor and mTORC1 by salinomycin in prostate cancer.
Mirkheshti N; Park S; Jiang S; Cropper J; Werner SL; Song CS; Chatterjee B
Oncotarget; 2016 Sep; 7(38):62240-62254. PubMed ID: 27557496
[TBL] [Abstract][Full Text] [Related]
14. Impact of genetic alterations on mTOR-targeted cancer therapy.
Sun SY
Chin J Cancer; 2013 May; 32(5):270-4. PubMed ID: 23489586
[TBL] [Abstract][Full Text] [Related]
15. Critical role of arachidonic acid-activated mTOR signaling in breast carcinogenesis and angiogenesis.
Wen ZH; Su YC; Lai PL; Zhang Y; Xu YF; Zhao A; Yao GY; Jia CH; Lin J; Xu S; Wang L; Wang XK; Liu AL; Jiang Y; Dai YF; Bai XC
Oncogene; 2013 Jan; 32(2):160-70. PubMed ID: 22349822
[TBL] [Abstract][Full Text] [Related]
16. Chronic activation of mTOR complex 1 is sufficient to cause hepatocellular carcinoma in mice.
Menon S; Yecies JL; Zhang HH; Howell JJ; Nicholatos J; Harputlugil E; Bronson RT; Kwiatkowski DJ; Manning BD
Sci Signal; 2012 Mar; 5(217):ra24. PubMed ID: 22457330
[TBL] [Abstract][Full Text] [Related]
17. Distinct signaling mechanisms of mTORC1 and mTORC2 in glioblastoma multiforme: a tale of two complexes.
Jhanwar-Uniyal M; Gillick JL; Neil J; Tobias M; Thwing ZE; Murali R
Adv Biol Regul; 2015 Jan; 57():64-74. PubMed ID: 25442674
[TBL] [Abstract][Full Text] [Related]
18. Lkb1 inactivation is sufficient to drive endometrial cancers that are aggressive yet highly responsive to mTOR inhibitor monotherapy.
Contreras CM; Akbay EA; Gallardo TD; Haynie JM; Sharma S; Tagao O; Bardeesy N; Takahashi M; Settleman J; Wong KK; Castrillon DH
Dis Model Mech; 2010; 3(3-4):181-93. PubMed ID: 20142330
[TBL] [Abstract][Full Text] [Related]
19. Important role of the LKB1-AMPK pathway in suppressing tumorigenesis in PTEN-deficient mice.
Huang X; Wullschleger S; Shpiro N; McGuire VA; Sakamoto K; Woods YL; McBurnie W; Fleming S; Alessi DR
Biochem J; 2008 Jun; 412(2):211-21. PubMed ID: 18387000
[TBL] [Abstract][Full Text] [Related]
20. Tumor Suppressor Folliculin Regulates mTORC1 through Primary Cilia.
Zhong M; Zhao X; Li J; Yuan W; Yan G; Tong M; Guo S; Zhu Y; Jiang Y; Liu Y; Jiang Y
J Biol Chem; 2016 May; 291(22):11689-97. PubMed ID: 27072130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
